Skip to main content
. 2018 Jul 19;9:412. doi: 10.3389/fendo.2018.00412

Figure 1.

Figure 1

Effects of pioglitazone, dapagliflozin and combination on body weight, blood glucose, kidney weight, and albuminuria. Graph depicting (A) body weight and (B) random blood glucose concentration in vehicle (black square, ■), pioglitazone (30 mg/kg/day, white circle, ◦), dapagliflozin (1 mg/kg/day,white square □), and combination (30 mg/kg/day of pioglitazone and 1 mg/kg/day of dapagliflozin, black circle, •) during 9 week of study period. (C) Measurement of both kidney weight after 9 weeks treatment in vehicle (PBS), pioglitazone (30 mg/kg/day), dapagliflozin (1 mg/kg/day), and combination (30 mg/kg/day of pioglitazone and 1 mg/kg/day of dapagliflozin). (D) Measurements of urine albumin to creatinine ratio after 8 weeks treatment in vehicle (PBS), pioglitazone (30 mg/kg/day), dapagliflozin (1 mg/kg/day), and combination (30 mg/kg/day of pioglitazone and 1 mg/kg/day of dapagliflozin). Data are means ± SEM (vehicle n = 5, monotherapy n = 8, combination therapy n = 7). *P < 0.05 vs. vehicle by one-way ANOVA and Tukey's post-hoc test.